Curis, Inc.
Feb 3, 2015
PDF
Add to Briefcase

Curis to Present at the 2015 Bio CEO and Investor Conference

LEXINGTON, Mass., Feb. 3, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused biotechnology company developing novel drug candidates for the treatment of human cancers, today announced that the Company will present at the 2015 Bio CEO and Investor Conference at 2:30 p.m. ET on Tuesday, February 10, 2015, in New York City.

Dr. Ali Fattaey, President and Chief Executive Officer, will provide an overview of Curis' pipeline and discuss Curis' recent entry into a broad collaboration with Aurigene in the areas of immuno-oncology and precision oncology.

A corresponding webcast of the presentation can be accessed by visiting:

http://www.veracast.com/webcasts/bio/ceoinvestor2015/56220328477.cfm

The webcast will be archived shortly after the live event and available for 30 days following the conference, and also available for 30 days on the Investor Relations section of the Curis website at www.curis.com.

About Curis, Inc.

Curis is a biotechnology company focused on the development and commercialization of novel drug candidates for the treatment of human cancers. Curis' pipeline of drug candidates includes CUDC-907, a dual HDAC and PI3K inhibitor, CUDC-427, a small molecule antagonist of IAP proteins, and Debio 0932 (CUDC-305), an oral HSP90 inhibitor. Curis is also engaged in a broad collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis expects to exercise options to exclusively license oral small molecules antagonists of PDL-1 and IRAK4, with IND application filings for both programs planned for 2015. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are developing and commercializing Erivedge®, the first and only FDA-approved medicine for the treatment of advanced basal cell carcinoma.

For more information, visit Curis' website at www.curis.com.

CONTACT: For More Information:

         Mani Mohindru, Ph.D.

         Vice President, Corporate Strategy and Investor Relations

         Curis, Inc.

         617-503-6605

         mmohindru@curis.com

         

         Michael P. Gray

         Chief Business and Financial Officer

         Curis, Inc.

         617-503-6632

         mgray@curis.com